CST
ABBV icon

Charles Schwab Trust’s AbbVie ABBV Stock Holding History

Charles Schwab Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.97M Buy
31,692
+23
+0.1% +$4.95K 0.44% 39
2026
Q1 		$6.89M Sell
31,669
-1,345
-4% -$298K 0.45% 40
2025
Q4 		$7.54M Buy
33,014
+909
+3% +$207K 0.5% 40
2025
Q3 		$7.43M Buy
32,105
+15,502
+93% +$3.16M 0.5% 39
2025
Q2 		$3.08M Sell
16,603
-2,352
-12% -$437K 0.23% 53
2025
Q1 		$3.97M Sell
18,955
-2,648
-12% -$515K 0.33% 43
2024
Q4 		$3.84M Buy
21,603
+288
+1% +$53K 0.33% 42
2024
Q3 		$4.21M Sell
21,315
-100
-0.5% -$18.7K 0.36% 41
2024
Q2 		$3.67M Buy
21,415
+830
+4% +$137K 0.34% 42
2024
Q1 		$3.75M Sell
20,585
-4,511
-18% -$777K 0.35% 40
2023
Q4 		$3.89M Buy
25,096
+904
+4% +$132K 0.38% 43
2023
Q3 		$3.61M Buy
24,192
+4,821
+25% +$708K 0.41% 43
2023
Q2 		$2.67M Sell
19,371
-304
-2% -$44.6K 0.32% 42
2023
Q1 		$3.14M Buy
19,675
+1,556
+9% +$238K 0.38% 40
2022
Q4 		$2.93M Buy
18,119
+2,667
+17% +$409K 0.39% 44
2022
Q3 		$2.07M Buy
15,452
+254
+2% +$36.4K 0.35% 48
2022
Q2 		$2.33M Sell
15,198
-170
-1% -$26K 0.48% 33
2022
Q1 		$2.49M Buy
15,368
+596
+4% +$86.6K 0.44% 35
2021
Q4 		$2M Sell
14,772
-25
-0.2% -$2.95K 0.32% 44
2021
Q3 		$1.6M Buy
14,797
+146
+1% +$16.7K 0.31% 58
2021
Q2 		$1.65M Sell
14,651
-228
-2% -$25.7K 0.32% 59
2021
Q1 		$1.61M Buy
14,879
+209
+1% +$22.4K 0.33% 56
2020
Q4 		$1.57M Hold
14,670
– – 0.38% 60
2020
Q3 		$1.28M Buy
14,670
+230
+2% +$21.7K 0.39% 56
2020
Q2 		$1.42M Buy
14,440
+6,688
+86% +$589K 0.47% 51
2020
Q1 		$591K Buy
7,752
+2,325
+43% +$198K 0.24% 85
2019
Q4 		$481K Hold
5,427
– – 0.19% 107
2019
Q3 		$397K Buy
+5,427
New +$372K 0.19% 97

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab Trust's ABBV Position: Q2 2026 in Review

Charles Schwab Trust increased its AbbVie (ABBV) stake by 0.07% in Q2 2026, buying an estimated $4.95K and bringing the position to 31,692 shares worth $7.97M. The position accounts for 0.44% of the portfolio, ranked #39.

Charles Schwab Trust first reported a position in ABBV in Q3 2019 and has held it in 28 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Charles Schwab Trust held 31,692 shares of AbbVie worth $7.97M as of Q2 2026.
  • Charles Schwab Trust bought 23 AbbVie shares in Q2 2026, an estimated $4.95K.
  • AbbVie made up 0.44% of Charles Schwab Trust's portfolio in Q2 2026, its #39 holding.
  • Charles Schwab Trust first reported a position in AbbVie in Q3 2019 and has held it in 28 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Charles Schwab Trust's 13F filing for Q2 2026, filed 10 Jul 2026.